Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi: 10.1158/1055-9965.EPI-15-0578.
   PubMed Web of Science ®Google Scholar
• Mun EJ, Babiker HM, Weinberg U, et al. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res. 2018;24(2):266–275. doi: 10.1158/1078-0432.CCR-17-1117.
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta GD, Kildani B, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74(2):106–133. doi: 10.1016/j.critrevonc.2010.01.010.
   PubMed Web of Science ®Google Scholar
• Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–196. doi: 10.1016/j.ejphar.2018.07.034.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Fountzilas E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019. doi: 10.1016/j.ctrv.2020.102019.
   PubMed Web of Science ®Google Scholar
• Appleman L. Multifactorial, Biomarker-Based predictive models for immunotherapy response enter the arena. J Natl Cancer Inst. 2021;113(1):7–8. doi: 10.1093/jnci/djaa077.
   PubMedGoogle Scholar
• Lemaire V, Shemesh CS, Rotte A, et al. Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. J Exp Clin Cancer Res. 2021;40(1):311. doi: 10.1186/s13046-021-02111-5.
   PubMed Web of Science ®Google Scholar
• Luo X-Y, Wu K-M, He X-X, et al. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res. 2021;40(1):172. doi: 10.1186/s13046-021-01968-w.
   PubMed Web of Science ®Google Scholar
• Looi C-K, Chung FF-L, Leong C-O, et al. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019;38(1):162. doi: 10.1186/s13046-019-1153-8.
   PubMed Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi: 10.1038/s41573-018-0006-z.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. doi: 10.3322/caac.21596.
   PubMed Web of Science ®Google Scholar
• Rotte A. Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary. Ann Transl Med. 2023;11(5):227–227. doi: 10.21037/atm-22-6564.
   PubMedGoogle Scholar
• Yi M, Zheng X, Niu M, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.
   PubMed Web of Science ®Google Scholar
• López-Soto A, Gonzalez S, Folgueras AR. IFN signaling and ICB resistance: time is on tumor’s side. Trends Cancer. 2017;3(3):161–163. doi: 10.1016/j.trecan.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. doi: 10.1182/blood-2017-06-741033.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Zhao L, Cheng S, Fan L, et al. TIM-3: an update on immunotherapy. Int Immunopharmacol. 2021;99:107933. doi: 10.1016/j.intimp.2021.107933.
   PubMed Web of Science ®Google Scholar
• Guo L, Wei R, Lin Y, et al. Clinical and recent patents applications of PD-1/PD-L1 targeting immunotherapy in cancer treatment-Current progress, strategy, and future perspective. Front Immunol. 2020;11:1508. doi: 10.3389/fimmu.2020.01508.
   PubMed Web of Science ®Google Scholar
• Wei R, Guo L, Wang Q, et al. Targeting PD-L1 protein: translation, modification and transport. Curr Protein Pept Sci. 2019;20(1):82–91. doi: 10.2174/1389203719666180928105632.
   PubMed Web of Science ®Google Scholar
• Guo L, Tang X, Wong SW, et al. Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications. Front Pharmacol. 2022;13:1022129. doi: 10.3389/fphar.2022.1022129.
   PubMed Web of Science ®Google Scholar
• Larsen TV, Hussmann D, Nielsen AL. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer. Cancer Commun. 2019;39(1):30. doi: 10.1186/s40880-019-0376-6.
   PubMedGoogle Scholar
• Wu Y, Chen W, Xu ZP, et al. PD-L1 distribution and perspective for cancer immunotherapy-Blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022. doi: 10.3389/fimmu.2019.02022.
   PubMed Web of Science ®Google Scholar
• Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023–5039. doi: 10.2147/OTT.S105862.
   PubMed Web of Science ®Google Scholar
• Helou DG, Shafiei-Jahani P, Lo R, et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun. 2020;11(1):3998. doi: 10.1038/s41467-020-17813-1.
   PubMed Web of Science ®Google Scholar
• Moral JA, Leung J, Rojas LA, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579(7797):130–135. doi: 10.1038/s41586-020-2015-4.
   PubMed Web of Science ®Google Scholar
• Bartemes KR, Kita H. Roles of innate lymphoid cells (ILCs) in allergic diseases: the 10-year anniversary for ILC2s. J Allergy Clin Immunol. 2021;147(5):1531–1547. doi: 10.1016/j.jaci.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Bouchery T, Le Gros G, Harris N. ILC2s-Trailblazers in the host response against intestinal helminths. Front Immunol. 2019;10:623. doi: 10.3389/fimmu.2019.00623.
   PubMed Web of Science ®Google Scholar
• Wan J, Wu Y, Huang L, et al. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8(+) T cells. Cancer Lett. 2021;502:34–43. doi: 10.1016/j.canlet.2021.01.002.
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Chevalier MF, Derré L, et al. The pro- and anti-tumor role of ILC2s. Semin Immunol. 2019;41:101276. doi: 10.1016/j.smim.2019.04.004.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–562. doi: 10.1016/j.ccell.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Taylor S, Huang Y, Mallett G, et al. PD-1 regulates KLRG1(+) group 2 innate lymphoid cells. J Exp Med. 2017;214(6):1663–1678. doi: 10.1084/jem.20161653.
   PubMed Web of Science ®Google Scholar
• Kamada T, Togashi Y, Tay C, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999–10008. doi: 10.1073/pnas.1822001116.
   PubMed Web of Science ®Google Scholar
• Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
   PubMed Web of Science ®Google Scholar
• Kuol N, Stojanovska L, Nurgali K, et al. PD-1/PD-L1 in disease. Immunotherapy. 2018;10(2):149–160. doi: 10.2217/imt-2017-0120.
   PubMed Web of Science ®Google Scholar
• Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021;12(9):2735–2746. doi: 10.7150/jca.57334.
   PubMed Web of Science ®Google Scholar
• Gong J, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.
   PubMed Web of Science ®Google Scholar
• Khan M, Zhao Z, Arooj S, et al. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460. doi: 10.3389/fimmu.2020.587460.
   PubMed Web of Science ®Google Scholar
• Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol Immunol. 2019;16(3):225–235. doi: 10.1038/s41423-019-0210-8.
   PubMed Web of Science ®Google Scholar
• Wan J, Cai W, Wang H, et al. Role of type 2 innate lymphoid cell and its related cytokines in tumor immunity. J Cell Physiol. 2020;235(4):3249–3257. doi: 10.1002/jcp.29287.
   PubMed Web of Science ®Google Scholar
• Ercolano G, Falquet M, Vanoni G, et al. ILC2s: new actors in tumor immunity. Front Immunol. 2019;10:2801. doi: 10.3389/fimmu.2019.02801.
   PubMed Web of Science ®Google Scholar
• Bruchard M, Ghiringhelli F. ILC2s in cancer: context matters. Nat Immunol. 2021;22(7):804–806. doi: 10.1038/s41590-021-00945-x.
   PubMed Web of Science ®Google Scholar